Current Report Filing (8-k)
March 31 2020 - 04:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported): March 30, 2020
OWC
Pharmaceutical Research Corp.
(Exact
Name of Issuer as Specified in Charter)
Delaware
|
|
000-54856
|
|
98-0573566
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification Number)
|
|
2
Ben Gurion St., Ramat Gan
Israel
5257334
|
|
|
|
4514760
|
(Address
of Principal Executive Offices)
|
|
|
|
(Zip
Code)
|
+972-72-260-8004
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
Stock
|
|
OWCP
|
|
OTCPQB
|
Item
8.01. Other Events.
On
March 30, 2020, the board of directors (the “Board”) of OWC Pharmaceutical Research Corp. (the “Company”),
approved the deregistration of the Company’s common stock under Section 12(g) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and the suspension of the Company’s reporting obligations under Section 13(a)
and 15(d) of the Exchange Act (the “Deregistration”). The Company intends to file a Form 15 with the Securities and
Exchange Commission (the “SEC”) on or about March 31, 2020 to effect the Deregistration. Upon the filing of the Form
15, the Company’s obligation to file periodic and current reports with the SEC, including Forms 10-K, 10-Q and 8-K, will
be immediately suspended. In addition, effective March 31, 2020, the Company’s common stock will no longer be eligible for
quotation on the OTC QB.
On
March 31, 2020, the Company issued a press release announcing its intention to effect the Deregistration. A copy of the press
release is attached hereto as Exhibit 99.1.
Item
9.01. Financial Information and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
March 31, 2020
|
OWC
PHARMACEUTICAL RESEARCH CORP.
|
|
|
|
|
By:
|
/s/
Zvi Riterband
|
|
Name:
|
Zvi
Riterband
|
|
Title:
|
Chief
Executive Officer
|
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Feb 2024 to Mar 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Mar 2023 to Mar 2024